SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bosco who wrote (1099)3/19/2001 4:50:28 PM
From: Londo  Read Replies (1) of 1298
 
Well, when ABGX was up at 70 bucks a share, I didn't take it very seriously.. and CEGE management probably didn't either, considering that the last secondary offering of stock they sold off another near-million shares..

But at 20 bucks a share, ABGX is much closer to the 'reality level' than it was at 70 bucks.. that's why I think its OK to include its full market valuation in this equation.. I don't think CEGE management will touch their ABGX stake until ABGX's market cap climbs significantly higher than the 1.6 billion its trading for right now.

Is the Phase I you are referring to the Pancreatic GVAX? The results of the Phase II on that indication should be interesting to say the least.. the CFO (on one of those presentations) said that if they get the same results as they did for the Phase I trial, they'd take it to the FDA..

TKTX/AMGN will probably provide small royalty revenues in 2003 for CEGE due to european sales.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News